De Novo Classification Requests: A Practical Guide for Devices Without a Predicate

When Your Device Does Not Fit the Mold: Understanding the De Novo Pathway

You have built something genuinely new. Your device does not look like anything already on the market, and no legally marketed predicate exists to support a 510(k) submission. For many medical device founders, that realization triggers a moment of panic. It should not. The FDA De Novo classification request process exists precisely for this situation, and when executed correctly, it is a legitimate and strategic route to market for novel, low-to-moderate risk devices.

This post breaks down what the De Novo pathway actually involves, who it is right for, and what it takes to build a submission that earns a favorable classification order from FDA.

What Is a De Novo Classification Request?

The De Novo process is authorized under Section 513(f)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and is codified in 21 CFR Part 860, Subpart D. It allows a device sponsor to request that FDA classify a novel device into Class I or Class II, establishing new special controls specific to that device type.

Before the pathway was modernized by the 21st Century Cures Act in 2016, sponsors had to first receive a Not Substantially Equivalent (NSE) determination from a 510(k) before pursuing De Novo. Today, under 21 CFR 860.257, you can submit a De Novo request directly to FDA without going through 510(k) first. This direct route saves significant time and eliminates the cost of a failed 510(k).

If FDA grants your De Novo request, three important things happen:

• Your device is classified into Class I or Class II with device-specific special controls
• Your device becomes an established predicate for future 510(k) submitters in that device category
• FDA publishes a classification regulation that benefits the entire industry

That third point is underappreciated. A successful De Novo does not just get your device cleared. It shapes the regulatory landscape for the device type you created.

Is De Novo Right for Your Device?

De Novo is appropriate when your device presents a novel technology or intended use that poses low to moderate risk, but general controls alone are insufficient to provide reasonable assurance of safety and effectiveness. If your device clearly poses high risk, you are looking at a PMA under 21 CFR Part 814, not De Novo.

Common scenarios where De Novo is the right call include:

• A software-based diagnostic tool with no cleared predicate in your specific intended use population
• A novel combination of existing technologies that creates a meaningfully different risk profile
• A device with a new physiological measurement modality that FDA has not classified before
• An AI/ML-driven device where predicate-based substantial equivalence arguments are untenable

If you have exhausted a predicate search and your best candidates have meaningful differences in intended use or technology that you cannot bridge, De Novo deserves serious consideration. The worst thing you can do is force a weak 510(k) with a distant predicate and invite a Not Substantially Equivalent determination months into your review.

What Goes Into a De Novo Submission?

FDA's definitive guidance on this is the October 2021 document titled 'De Novo Classification Process (Evaluation of Automatic Class III Designation).' Your submission should be built around the core elements FDA expects to evaluate.

Device Description and Indications for Use

These must be precise. FDA will use your indications statement to draft the classification regulation if your request is granted. Vague or overly broad indications create problems during review and can narrow your cleared indication in ways you did not anticipate.

Risk Analysis and Risk-Benefit Assessment

You need a rigorous risk analysis, typically structured per ISO 14971:2019, that identifies hazards, estimates risk, and explains why residual risks are acceptable given the device's benefits. FDA reviewers use your risk analysis to evaluate whether Class II controls are sufficient or whether Class III with PMA would be more appropriate.

Proposed Special Controls

This is where many sponsors underinvest. You must propose specific special controls that, together with general controls under 21 CFR Part 820 and your indications for use, provide reasonable assurance of safety and effectiveness. Special controls typically include performance standards, postmarket surveillance requirements, labeling requirements, and specific testing requirements. FDA may modify your proposed controls, but submitting well-reasoned proposals signals regulatory sophistication and shortens the negotiation cycle.

Performance Data

Bench testing, biocompatibility per ISO 10993, software documentation per FDA's Software guidance, clinical data if applicable, and any cybersecurity documentation under FDA's 2023 cybersecurity guidance should all be addressed based on your device type and risk profile.

Timeline and Practical Expectations

FDA's target total time for De Novo review under MDUFA V is 150 days from acceptance. However, acceptance review alone takes up to 15 days, and FDA frequently issues Additional Information (AI) requests during substantive review that pause the clock and extend real-world timelines. Plan for 12 to 18 months from submission to decision in most cases, particularly for novel device types that require significant internal FDA deliberation.

Strategic Advantages Beyond Market Clearance

Do not overlook the business value of being the De Novo holder. Competitors who want to market a substantially equivalent device must reference your device as their predicate in a 510(k). That positions your cleared device as the gold standard for the device type and creates a durable first-mover regulatory advantage. Investors and acquirers understand this. A De Novo classification order is a meaningful asset on your regulatory dossier.

Do Not Navigate This Alone

De Novo submissions demand deep regulatory strategy, precise technical writing, and a thorough understanding of how FDA classifies risk. A misstep in your proposed special controls or an underpowered risk-benefit analysis can result in a denial or a request to submit a PMA instead, which costs you years and millions of dollars.

At ADB Consulting and CRO Inc., Andre Butler and the team have helped medical device companies across therapeutic areas structure and execute De Novo submissions that align with FDA expectations from the first interaction. We understand what FDA is looking for because we have been in these conversations, and we build submissions that get devices classified and on the market.

If you are developing a novel device and are unsure whether De Novo is your path, book a free discovery call with our team. We will assess your device, your predicate landscape, and your timeline to give you a clear-eyed regulatory strategy on day one.

Visit adbccro.com to schedule your complimentary consultation today.